Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

Phase 2 Completed 221 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.

Timeline

Start: 2003-11
Primary completion: 2005-11
Completion: 2005-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Temsirolimus	Small molecule	—	Oral

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

Summary

Timeline

Drugs

Indications